Abivax SA Sponsored ADR is a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to help stabilize the immune response in chronic inflammatory diseases. The company’s lead program centers on obefazimod, a clinical-stage candidate being studied for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Abivax SA Sponsored ADR operates as a sponsored American Depositary Receipt representing the company’s ordinary shares, giving U.S. investors access to a France-based biopharmaceutical developer. Its current work is centered on clinical research, drug development, and advancing treatments aimed at complex immune-mediated conditions. Based in Paris, Abivax SA remains positioned within the global biotechnology market as a specialist in immunology-focused therapies and late-stage clinical development.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€332M
▼ -90.7% YoY
Op. Margin
–
ROIC
-65.34%
▼ -2.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€179M
▼ -4.2% YoY
Op. Cash Flow (TTM)
-€178M
▼ -4.6% YoY
Net Debt
-€529M
Net Cash Position
Cash & Equiv.
€530M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ABVX
Held by ETFs
ABVX is in 16 US ETFs. The largest of them, with ABVX's weight in each:
Fidelity Nasdaq Composite Index ETFONEQ0.02%of the fund
iShares Biotechnology ETFIBB0.45%of the fund
- APActivePassive International Equity ETFAPIE0.02%of the fund
Morgan Stanley Pathway Small-Mid Cap Equity ETFMSSM0.26%of the fund
- NPNPF Core Equity ETFNPFE0.00%of the fund
Goldman Sachs Hedge Industry VIP ETFGVIP1.96%of the fund
Abivax SA (ABVX) in three numbers
Questions about Abivax SA
Is Abivax SA a high-quality business?
Abivax SA scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$529M, and its weakest is return on capital at -65.3%. The Quality tab shows every check against its target.
Does Abivax SA (ABVX) pay a dividend?
No. Abivax SA (ABVX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ABVX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.